110 related articles for article (PubMed ID: 10757416)
1. Membrane permeation by multidrug-resistance-modulators and non-modulators: effects of hydrophobicity and electric charge.
Castaing M; Brouant P; Loiseau A; Santelli-Rouvier C; Santelli M; Alibert-Franco S; Mahamoud A; Barbe J
J Pharm Pharmacol; 2000 Mar; 52(3):289-96. PubMed ID: 10757416
[TBL] [Abstract][Full Text] [Related]
2. Designing multidrug-resistance modulators circumventing the reverse pH gradient in tumours.
Castaing M; Loiseau A; Dani M
J Pharm Pharmacol; 2001 Jul; 53(7):1021-8. PubMed ID: 11480537
[TBL] [Abstract][Full Text] [Related]
3. Thermal dependence of multidrug-resistant-modulator efficiency: a study in anionic liposomes.
Castaing M; Loiseau A; Dani M
J Pharm Pharmacol; 2000 Oct; 52(10):1171-8. PubMed ID: 11092560
[TBL] [Abstract][Full Text] [Related]
4. Effects of cholesterol on dye leakage induced by multidrug-resistance modulators from anionic liposomes.
Castaing M; Loiseau A; Djoudi L
Eur J Pharm Sci; 2003 Jan; 18(1):81-8. PubMed ID: 12554076
[TBL] [Abstract][Full Text] [Related]
5. Interactions between verapamil and neutral and acidic liposomes: effects of the ionic strength.
Castaing M; Loiseau A; Mulliert G
Biochim Biophys Acta; 2003 Apr; 1611(1-2):107-14. PubMed ID: 12659951
[TBL] [Abstract][Full Text] [Related]
6. Synergy between verapamil and other multidrug -resistance modulators in model membranes.
Castaing M; Loiseau A; Cornish-Bowden A
J Biosci; 2007 Jun; 32(4):737-46. PubMed ID: 17762146
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance modulator interactions with neutral and anionic liposomes: membrane binding affinity and membrane perturbing activity.
Castaing M; Loiseau A; Mulliert G
J Pharm Pharmacol; 2005 May; 57(5):547-54. PubMed ID: 15901343
[TBL] [Abstract][Full Text] [Related]
8. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
9. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery.
Webb MS; Wheeler JJ; Bally MB; Mayer LD
Biochim Biophys Acta; 1995 Sep; 1238(2):147-55. PubMed ID: 7548129
[TBL] [Abstract][Full Text] [Related]
10. The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids.
Gallois L; Fiallo M; Laigle A; Priebe W; Garnier-Suillerot A
Eur J Biochem; 1996 Nov; 241(3):879-87. PubMed ID: 8944778
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
12. Presence of anionic phospholipids rules the membrane localization of phenothiazine type multidrug resistance modulator.
Wesołowska O; Hendrich AB; Motohashi N; Kawase M; Dobryszycki P; Ozyhar A; Michalak K
Biophys Chem; 2004 Jun; 109(3):399-412. PubMed ID: 15110937
[TBL] [Abstract][Full Text] [Related]
13. Interactions of phenothiazines with lipid bilayer and their role in multidrug resistance reversal.
Michalak K; Wesolowska O; Motohashi N; Molnar J; Hendrich AB
Curr Drug Targets; 2006 Sep; 7(9):1095-105. PubMed ID: 17017888
[TBL] [Abstract][Full Text] [Related]
14. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.
Joguparthi V; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability.
Drori S; Eytan GD; Assaraf YG
Eur J Biochem; 1995 Mar; 228(3):1020-9. PubMed ID: 7737146
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study.
Gallois L; Fiallo M; Garnier-Suillerot A
Biochim Biophys Acta; 1998 Mar; 1370(1):31-40. PubMed ID: 9518541
[TBL] [Abstract][Full Text] [Related]
17. Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion.
Flaten GE; Dhanikula AB; Luthman K; Brandl M
Eur J Pharm Sci; 2006 Jan; 27(1):80-90. PubMed ID: 16246536
[TBL] [Abstract][Full Text] [Related]
18. Drug partition chromatography on immobilized porcine intestinal brush border membranes.
Engvall C; Lundahl P
J Chromatogr A; 2004 Mar; 1031(1-2):107-12. PubMed ID: 15058573
[TBL] [Abstract][Full Text] [Related]
19. New phenothiazine-type multidrug resistance modifiers: anti-MDR activity versus membrane perturbing potency.
Hendrich AB; Wesołowska O; Motohashi N; Molnár J; Michalak K
Biochem Biophys Res Commun; 2003 May; 304(2):260-5. PubMed ID: 12711308
[TBL] [Abstract][Full Text] [Related]
20. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge.
Lampidis TJ; Kolonias D; Podona T; Israel M; Safa AR; Lothstein L; Savaraj N; Tapiero H; Priebe W
Biochemistry; 1997 Mar; 36(9):2679-85. PubMed ID: 9054575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
